CCT - Crypto Currency Tracker logo CCT - Crypto Currency Tracker logo
CoinDesk 2025-10-02 14:03:26

Crypto Market Maker GSR to Acquire FINRA-Registered Broker-Dealer Equilibrium Capital Services

Cryptocurrency market maker GSR has signed an agreement to acquire Equilibrium Capital Services, a Portland-based broker-dealer registered with the SEC and a member of FINRA. The deal, which is still pending regulatory approval, marks a step toward expanding GSR’s regulated presence in the United States. GSR did not disclose the terms of the Equilibrium Capital deal in its press release. Equilibrium Capital’s registration allows it to provide brokerage services under U.S. securities laws. By bringing it under its umbrella, GSR expects to offer institutional clients a more direct route into digital assets while operating within established compliance frameworks. GSR executives framed the move as part of a longer-term strategy to deepen its institutional ties in the U.S. Xin Song, the firm’s CEO, said the acquisition reflects GSR’s commitment to serving both entrepreneurs and large investors who want regulated access to crypto markets. The acquisition comes as regulators continue to shape the rules governing digital assets in the U.S. For a firm like GSR — best known for its global market-making and liquidity services — having a broker-dealer license could open doors to products that fall under securities oversight. To manage the acquisition process, GSR engaged Compliance Exchange Group (CXG) for regulatory guidance and BrokerDealerForSale.com for the acquisition of Equilibrium Capital Services. GSR has been steadily building its regulated services portfolio. In recent months, the firm has expanded institutional access to tokenized real-world assets through a partnership with DigiFT, according to a press release. The market making firm also invested in Maverix Securities to support the development of regulated structured products, and led digital-asset treasury investment strategies for Nasdaq-listed companies, including MEI Pharma and Upexi.

면책 조항 읽기 : 본 웹 사이트, 하이퍼 링크 사이트, 관련 응용 프로그램, 포럼, 블로그, 소셜 미디어 계정 및 기타 플랫폼 (이하 "사이트")에 제공된 모든 콘텐츠는 제 3 자 출처에서 구입 한 일반적인 정보 용입니다. 우리는 정확성과 업데이트 성을 포함하여 우리의 콘텐츠와 관련하여 어떠한 종류의 보증도하지 않습니다. 우리가 제공하는 컨텐츠의 어떤 부분도 금융 조언, 법률 자문 또는 기타 용도에 대한 귀하의 특정 신뢰를위한 다른 형태의 조언을 구성하지 않습니다. 당사 콘텐츠의 사용 또는 의존은 전적으로 귀하의 책임과 재량에 달려 있습니다. 당신은 그들에게 의존하기 전에 우리 자신의 연구를 수행하고, 검토하고, 분석하고, 검증해야합니다. 거래는 큰 손실로 이어질 수있는 매우 위험한 활동이므로 결정을 내리기 전에 재무 고문에게 문의하십시오. 본 사이트의 어떠한 콘텐츠도 모집 또는 제공을 목적으로하지 않습니다.